Nyvepria

Active Ingredient(s): Pegfilgrastim-apgf
FDA Approved: * June 10, 2020
Pharm Company: * HOSPIRA INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Nyvepria Overview

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the production of white blood cells (neutrophils).[3] Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.[4] Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).&...

Read more Nyvepria Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Pegfilgrastim

Recent Nyvepria Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Pegfilgrastim-apgf
  • Injection: 6mg/0.6ml
  • Syringe: 6mg/0.6ml, 6mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Pegfilgrastim-apgf or a similar ingredient: (9 results)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 4 December 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA